Skip to main content
Premium Trial:

Request an Annual Quote

Pluvita Nabs Majority Stake in Diogenics

WASHINGTON, DC, Oct. 3 – Pluvita, a drug-discovery and development company, has acquired a majority stake in Diogenics, a privately held genomic firm, the companies said on Wednesday.

The acquisition, for an undisclosed amount, was designed to allow Pluvita to combine its bioinformatics, information management, and clinical databases with Diogenics’ wet-lab capabilities, model systems, and intellectual property assets, Pluvita said in a statement.  

“This is a key validation from a research organization of Pluvita’s unique model to accelerate the drug discovery and development process,” the company said before the start of the Biotechnology Industry Organization venture capital forum here this week, where it is participating. “The Diogenics acquisition is a collaborative partnership and serves as proof-of-principle of our unique approach to target and lead identification and optimization,” Pluvita CEO Gary J. Kurtzman added in a statement.

Diogenics, of Irvine, Calif., identifies and validates clinically relevant gene and protein targets in steroid hormone-responsive diseases, including prostate cancer, BPH, breast cancer, ovarian cancer, and other reproductive diseases, according to Pluvita. 

Beside Diogenics’ wet lab capabilities and intellectual property assets, Bethesda, Md.-based Pluvita will acquire a scientific team experienced in molecular biology, microarray technology, protein expression, immunology, reproductive biology, vaccine delivery, functional genomics, proteomics, structural biology, and bioinformatics, Pluvita said. 

The Diogenics acquisition is the first in a series of strategic relationships Pluvita plans over the next year, according to Pluvita.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.